Thursday, February 5, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Title Wolfe Research Analyst Initiates Coverage of Corteva with Outperform Rating and 67 Price Target

Elaine Mendonca by Elaine Mendonca
March 2, 2024
in Breaking News
0
Finance_Capitalistic
0
SHARES
9
VIEWS
Share on FacebookShare on Twitter

Wolfe Research analyst Chris Parkinson has recently started covering Corteva (NYSE: CTVA) with an Outperform rating. This analysis was initiated on February 29th and March 1st, 2024. According to Wolfe Research, Corteva has been given an “outperform” rating with a price target of $67.00. Capital IQ reports that the consensus among analysts also leans towards an outperform rating for Corteva, with price targets ranging from $53 to $70.

Corteva Inc. (CTVA) Stock Market Performance Analysis: March 2, 2024

On March 2, 2024, Corteva Inc. (CTVA) saw a positive performance in the stock market. The stock closed at $53.66, which was a $0.14 increase from the previous market close, representing a 0.26% rise in price. CTVA’s performance on this day was notable for a few reasons.

One key indicator of CTVA’s performance is its position relative to its 52-week range and its 200-day simple moving average. CTVA was trading in the middle of its 52-week range on March 2, indicating that the stock has not reached extreme highs or lows compared to its performance over the past year. Additionally, CTVA was trading above its 200-day simple moving average, suggesting that the stock has been on an overall upward trend in the longer term.

While CTVA’s price increase on March 2 was relatively small, the stock’s stability in after-hours trading is also worth noting. The fact that CTVA remained unchanged in after-hours trading indicates that investors were generally confident in the stock’s performance and did not feel the need to sell off their shares after the market closed.

Overall, CTVA’s performance on March 2, 2024, reflects a stable and positive trend in the stock market. With its position in the middle of its 52-week range and above its 200-day simple moving average, CTVA appears to be a solid investment option for investors looking for steady growth in the agricultural sector.

CTVA Stock Performance Review: Mixed Results in Financial Metrics on March 2, 2024

On March 2, 2024, CTVA stock showed mixed performances in terms of its financial metrics. According to data from CNN Money, the company reported total revenue of $17.23 billion for the past year, which remained flat compared to the previous year. Similarly, the total revenue for the fourth quarter was reported at $3.71 billion, also holding flat since the previous quarter.

In terms of net income, CTVA reported a net income of $735.00 million for the past year, representing a decrease of 35.92% compared to the previous year. However, the net income for the fourth quarter showed a positive trend, with a reported loss of $233.00 million, representing an increase of 26.73% since the previous quarter.

Earnings per share (EPS) for CTVA stock were reported at $1.03 for the past year, showing a decrease of 34.79% compared to the previous year. The EPS for the fourth quarter was reported at -$0.36, which remained flat compared to the previous quarter.

Overall, CTVA stock showed mixed performances in its financial metrics on March 2, 2024. While total revenue remained flat, net income showed a decrease compared to the previous year but an increase compared to the previous quarter. Earnings per share also showed a decrease compared to the previous year but remained flat compared to the previous quarter. Investors and analysts will be closely monitoring CTVA’s financial performance in the coming quarters.

Tags: CTVA
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Analyst Optimistic about Eli Lilly Cos Promising Future

Finance_Accounting (2)

Analyst Maintains Neutral Rating on Forward Air Lowers Price Target

EEFT stock news

Analyst at Morgan Stanley Increases Price Target for Clearway Energy

Recommended

SKYX Platforms Stock

Marriott Partnership Signals Major Breakthrough for SKYX Platforms

5 months ago
Microsoft Stock

Microsoft’s AI Ambition: A High-Stakes Bet on Future Growth

18 hours ago
Turtle Beach Stock

Turtle Beach Forges PlayStation Alliance with New Gaming Headset

5 months ago
FLO stock news

Cemtrex Shares Surge After Halting Trading Due to Circuit Breaker

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

CureVac Delisted Following BioNTech Acquisition Completion

Strategic Robotics Partnership Signals New Growth Phase for EOS Defence

NexPoint Residential Trust Sets Date for Annual and Q4 2025 Results

PC Connection Set to Report Full-Year and Fourth Quarter Earnings

Fossil Group Stock Surges Past Key Technical Threshold

NextGen Healthcare: Strategic Wins and Industry Accolades Signal Sustained Momentum

Trending

Rolls Royce Stock
Defense & Aerospace

Rolls-Royce Shares: A Pivotal Period for Growth and Diversification

by Dieter Jaworski
February 5, 2026
0

The coming weeks represent a critical juncture for Rolls-Royce. The company is poised to demonstrate whether it...

Viking Therapeutics Stock

Viking Therapeutics: Investors Await Key Clinical Updates in Forthcoming Report

February 5, 2026
Solana Stock

Solana Faces Billions in Potential Token Supply Releases

February 5, 2026
CureVac Stock

CureVac Delisted Following BioNTech Acquisition Completion

February 5, 2026
EOS Stock

Strategic Robotics Partnership Signals New Growth Phase for EOS Defence

February 5, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Rolls-Royce Shares: A Pivotal Period for Growth and Diversification
  • Viking Therapeutics: Investors Await Key Clinical Updates in Forthcoming Report
  • Solana Faces Billions in Potential Token Supply Releases

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com